No title
PURPOSE: There is uncertainty whether ER-low tumors with a 1-10% immunohistochemical staining of nuclei represent a distinct molecular biological entity of BC, posing significant challenges for their clinical management and developing novel therapies. We aimed to elucidate ER-low tumor biology.EXPERIMENTAL DESIGN: We analyzed primary tumors included in a Swedish population-based SCAN-B BC cohort,
